Gerard Abess, MD
Family Medicine · Glens Falls, NYNPI 1467452441
Payments from drug & device makers
Across 121 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$741
- GSK$698
- Takeda Pharmaceuticals U.S.A., Inc.$235
- Novo Nordisk$165
- AstraZeneca$105
- Lilly USA, LLC$97
- plus $272 from 8 others
What the payments were for
- Food & beverage$2,30299%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $741 |
| GSK | 33 | $698 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $235 |
| Novo Nordisk | 8 | $165 |
| AstraZeneca | 7 | $105 |
| Lilly USA, LLC | 5 | $97 |
| Merck | 4 | $57 |
| Johnson & Johnson | 2 | $47 |
| Sanofi Pasteur Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $36 |
| Pfizer | 2 | $29 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$262
- UBRELVY$120
How this compares
$2,313 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 184 | $142,781 |
| JardianceEmpagliflozin | 85 | $107,862 |
| OzempicSemaglutide | 52 | $91,006 |
| TradjentaLinagliptin | 53 | $59,360 |
| XareltoRivaroxaban | 38 | $45,007 |
| FarxigaDapagliflozin Propanediol | 38 | $39,409 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $33,958 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $32,344 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $27,134 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $18,129 |
| TrulicityDulaglutide | 13 | $14,232 |
| JanuviaSitagliptin Phosphate | 15 | $10,664 |
| TrintellixVortioxetine Hydrobromide | 21 | $9,864 |
| Potassium Chloride | 79 | $9,392 |
| Rosuvastatin Calcium | 414 | $7,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $36 | $167,223138 claims |
| PfizerEliquis | $29 | $142,781184 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $698 | $96,770168 claims |
| Novo NordiskOzempic | $165 | $91,00652 claims |
| Johnson & JohnsonXarelto | $47 | $45,00738 claims |
| AstraZenecaFarxiga | $105 | $39,40938 claims |
| Lilly USA, LLCTrulicity | $97 | $14,23213 claims |
| MerckJanuvia | $57 | $10,66415 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $235 | $9,86421 claims |
| AbbVieSynthroid | $741 | $6,53682 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.
Other family medicine in Glens Falls
- Andrew GarnerGlens Falls$306K
- James NorthGlens Falls$186K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.